HYPOTHYROIDISM AMONG MULTIDRUG-RESISTANT TUBERCULOSIS TREATMENT IN SARABURI HOSPITAL
Article Sidebar
Main Article Content
Abstract
BACKGROUND : Hypothyroidism is an important side effect that found in multidrug-resistant tuberculosis (MDR-TB) treatment including ethionamide (Eto) and para-aminosalicylic acid(PAS). Recently, there were no research focusing on this hypothyroidism in thailand.
OBJECTIVE : The aim of this study was to determine the prevalence of hypothyroidism and the median time to hypothyroidism in patients with MDR-TB
METHODS : Retrospective chart review was conducted in patients with MDR-TB who registered in TB clinic at Saraburi hospital between 20 January 2009 and 15 October 2018. All patients were received Eto and/or PAS and TSH level during the study period. Hypothyroidism was recorded when TSH level was increased more than 10 mIU/mL or was diagnosed by physicians.
RESULT: Fifty-nine patients were included in this study. Hypothyroidism of 37 patients was about 62.7% (95% CI, 49.1-74.9). Median time to hypothyroidism was 126 days (IQR, 81-179). Kaplan-Meier survival curve was estimated that found 50 percent of patients who had developed hypothyroidism after beginning for 176 days
CONCLUSIONS AND DISCUSSIONS: More than half (62.7%) of MDR-TB patients who received Eto and/or PAS were developed hypothyroidism. Therefore, all patients who received Eto and/or PAS should be checked TSH level continuously during the period time of treatment with Eto and/or PAS.
KEYWORDS: Multidrug- Resistant Tuberculosis, Hypothyroidism
Article Details
References
Tuberculosis Control Programme Guidelines, Thailand,2013. Bangkok: The agricultural Co-operative
federation of Thailand; 2013
2. Ministry of Public Health. Department of Disease Control. Bureau of Tuberculosis. Guideline for
Programmatic Management of Drug-Resistant Tuberculosis. Bangkok: The agricultural Co-operative
federation of Thailand; 2015
3. Ministry of Public Health. Department of Disease Control. Bureau of Tuberculosis. National
Tuberculosis Control Programme Guidelines, Thailand, 2018. Bangkok: Aksorn-Graphic-and-
design;2018
4. World Health Organization. Guidelines for the programmatic management of drug-resistant
tuberculosis. Geneva, Switzerland: WHO; 2008
5. World Health Organization. Companion handbook to WHO guidelines programmatic
management of drug-resistant tuberculosis. Geneva, Switzerland: WHO; 2014
6. Drucker D, Eggo MC, Salit IE, Burrow GN. Ethionamide-induced goitroushypothyroidism. Ann
Intern Med. 1984; 100:837-9.
7. McDonnell ME, Braverman LE, Bernardo J. Hypothyroidism due to ethionamide. N Engl J
Med. 2005; 352:2757-9.
8. Davie HT, Galbraith HJ. Goitre and hypothyroidism developing during treatment with P.A.S.
BrMed J. 1953; 1:1261.
9. Hamilton RR. Effect of P.A.S. on the thyroid gland. Br Med J. 1953:1(4800):29-30. PubMed
PMID:12997825
10.Furin JJ, mitnick CD, Shin SS, Bayona J, Becerra MC, Singler JM, et al. Occurrence of
serious adverse in patients receiving community-based therapy for multidrug-resistant
tuberculosis. Int J Tuberc Lung Dis. 2001;5:648-55. PubMed PMID:11467371
11.Andries A, Isaakidis P, Das M, Khan S, Paryani R, Desai C, et al. High Rate of
Hypothyroidism in Multidrug-Resistant Tuberculosis Patients Co-Infected with HIV in Mumbai,
India. PloSOne(internet). 2013 (cited 2018 Nov 4);8(10):e78313. Available from:
https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0078313
12.Dutta BS, Hassa G, Waseem Q, Saheer S, Singh A, Ethionamide-induced hypothyroidism.
Int J Tuberc Lung Dis off J Int Union Against Tuberc Lung Dis. 2012;1G(1):141. http://dx.doi.
Org/10.5588/ijtld.11.0388.
13.Srivanichakorn W. Treatment for thyroid hormone deficiency. In: Phisalprapa P, Siwamogsatham S,
Sura T, editors. Ambulatory medicine The Survivors. Bangkok: Thepphenvanish; 2016.p.149-65
14.Satti H, Mafukidze A, Jooste PL, McLaughlin MM, Farmer PE, Seung KJ. High Rate of
Hypothyroidism among Patients Treated for MDR-TB in Lesotho. Int J Tuberc Lung Dis
(internet). 2012 (cited 2018 Nov 4);16(4), 468-72. Available from:
http://dx.doi.org/10.5588/ijtld.11.0615
15.Modongo C, Zetola NM. (2012) Prevalence of Hypothyroidism among MDR-TB Patients
in Botswana. Int J Tuberc Lung Dis. 2012;16(11):1561-2. doi: 10.5588/ijtld.12.0403. PubMed
PMID:23044454
16.Munivenkatappa S, Anil S, Naik B, Volkmann T, Sagili KD, Akshatha JS, et all. Drug-induced
Hypothyroidism during Anti-Tuberculosis Treatment of Multidrug-Resistant
